Annual Financials for Revolution Medicines Inc.
Fiscal year is January-December. All values USD millions. |
2018 | 2019 | 2020 | 2021 | 2022 |
5-year trend |
Sales/Revenue
|
20.17M | 50.04M | 42.98M | 29.39M | 35.38M | |
Sales Growth |
- | 148.16% | -14.10% | -31.62% | 20.38% | |
Cost of Goods Sold (COGS) incl. D&A |
1.76M | - | - | 7.33M | 9.66M | |
COGS excluding D&A |
- | - | - | - | - | |
Depreciation & Amortization Expense |
1.76M | 3.34M | 6.55M | 7.33M | 9.66M | |
Depreciation |
1.57M | 2.27M | 5.48M | 6.26M | 8.59M | |
Amortization of Intangibles |
198,000 | 1.07M | 1.07M | 1.07M | 1.07M | |
COGS Growth |
- | - | - | - | 31.70% | |
Gross Income |
18.4M | - | - | 22.06M | 25.72M | |
Gross Income Growth |
- | - | - | - | 16.62% | |
Gross Profit Margin |
- | - | - | - | 72.71% | NA |
|
2018 | 2019 | 2020 | 2021 | 2022 |
5-year trend |
SG&A Expense |
58.33M | 100.22M | 147.14M | 210.07M | 284M | |
Research & Development |
51.08M | 91.16M | 128.57M | 182.8M | 248.03M | |
Other SG&A |
7.25M | 9.06M | 18.56M | 27.27M | 35.97M | |
SGA Growth |
- | 71.82% | 46.81% | 42.77% | 35.20% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
2.52M | - | - | - | - | |
EBIT after Unusual Expense |
(42.45M) | - | - | - | - | |
Non Operating Income/Expense |
- | (597,000) | - | - | - | |
Non-Operating Interest Income |
777,000 | 2.19M | 2.24M | 929,000 | 9.15M | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
116,000 | 106,000 | 71,000 | 12,000 | - | |
Interest Expense Growth |
- | -8.62% | -33.02% | -83.10% | - | |
Gross Interest Expense |
116,000 | 106,000 | 71,000 | 12,000 | - | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(41.79M) | (52.04M) | (108.53M) | (187.09M) | (249.13M) | |
Pretax Income Growth |
- | -24.52% | -108.56% | -72.39% | -33.16% | |
Pretax Margin |
- | - | - | - | -704.14% | NA |
Income Tax |
- | (4.37M) | (371,000) | - | (420,000) | |
Income Tax - Current Domestic |
- | (4.37M) | (371,000) | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(41.79M) | (47.66M) | (108.16M) | (187.09M) | (248.71M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(41.79M) | (47.66M) | (108.16M) | (187.09M) | (248.71M) | |
Net Income Growth |
- | -14.06% | -126.92% | -72.98% | -32.93% | |
Net Margin Growth |
- | - | - | - | -702.95% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(41.79M) | (47.66M) | (108.16M) | (187.09M) | (248.71M) | |
Preferred Dividends |
7.03M | 14.24M | 2.22M | - | - | |
Net Income Available to Common |
(48.82M) | (61.9M) | (110.38M) | (187.09M) | (248.71M) | |
EPS (Basic) |
(0.83) | (1.05) | (1.66) | (2.57) | (3.08) | |
EPS (Basic) Growth |
- | -26.81% | -57.96% | -55.05% | -20.04% | |
Basic Shares Outstanding |
59M | 59M | 66.6M | 72.81M | 80.63M | |
EPS (Diluted) |
(0.83) | (1.05) | (1.66) | (2.57) | (3.08) | |
EPS (Diluted) Growth |
- | -26.81% | -57.96% | -55.05% | -20.04% | |
Diluted Shares Outstanding |
59M | 59M | 66.6M | 72.81M | 80.63M | |
EBITDA |
(38.17M) | (50.18M) | (104.15M) | (180.68M) | (248.62M) | |
EBITDA Growth |
- | -31.48% | -107.55% | -73.47% | -37.61% | |
EBITDA Margin |
- | - | - | - | -702.72% | NA |